Wistar Institute grants Horizon exclusive license , 9/16
September 2016—Horizon Discovery Group and the Wistar Institute announced that Horizon has taken an exclusive license to 153 of Wistar’s melanoma patient-derived xenograft models. Horizon’s distribution of the Wistar melanoma PDX collection will allow scientists worldwide to investigate the efficacy and safety of its drugs prior to trials in human populations.